Vanguard Capital Management
ELTX icon

Vanguard Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Vanguard Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
572,151
+53,513
+10% +$537K ﹤0.01% 3386
2026
Q1 		$5.54M Buy
+518,638
New +$5.01M ﹤0.01% 3017

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's ELTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Elicio Therapeutics (ELTX) stake by 10% in Q2 2026, buying an estimated $537K and bringing the position to 572,151 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3386.

Vanguard Capital Management first reported a position in ELTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.54M in Q1 2026. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Vanguard Capital Management held 572,151 shares of Elicio Therapeutics worth $2.24M as of Q2 2026.
  • Vanguard Capital Management bought 53,513 Elicio Therapeutics shares in Q2 2026, an estimated $537K.
  • Elicio Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3386 holding.
  • Vanguard Capital Management first reported a position in Elicio Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Elicio Therapeutics position peaked at $5.54M in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.